
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Cutaneous Manifestations and Dermatologic Adverse Events in IBD
A Clinical Update</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Cutaneous Manifestations and Dermatologic Adverse Events in IBD</strong><br><em>A Clinical Update</em></summary>
            <div>
                <ul><li>- <u>Journal</u>: Inflammatory Bowel Diseases, 2025</li><li>- <u>DOI</u>: https://doi.org/10.1093/ibd/izaf228</li><li>- <u>Type</u>: Review Article - Clinical</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the prevalence of Erythema Nodosum in CD and UC patients according to a recent meta-analysis?</li><li>- Which anti-TNF agents are most implicated in the development of paradoxical skin lesions?</li><li>- What is the recommended first-line systemic treatment for Pyoderma Gangrenosum?</li><li>- What is the recommended oral dose of valaciclovir for uncomplicated Herpes Zoster in immunocompetent patients?</li><li>- Which two specific JAK inhibitors have been identified in a meta-analysis to have a statistically significant association with Herpes Zoster?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>IBD & Extraintestinal Manifestations (EIMs) Overview</strong></summary>
            <div>
                <ul><li>- <b>Inflammatory Bowel Disease (IBD)</b> is an immune-mediated disease with chronic, relapsing-remitting gastrointestinal inflammation.</li><li>- The clinical picture is shaped by both GI symptoms and multiple EIMs.</li></ul>
                
        <details>
            <summary><strong>IBD Subtypes</strong></summary>
            <div>
                <ul><li>- <b>Ulcerative Colitis (UC)</b>: Nontransmural mucosal inflammation restricted to the colon.</li><li>- <b>Crohn’s Disease (CD)</b>: Transmural inflammation with skip lesions, affecting any part of the GI tract (mouth to anus).</li><li>- <b>Unclassified Colitis</b>: Affects <q>10% to 15%</q> of IBD cases, with overlapping features of UC and CD.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>EIMs Classification (ECCO Guidelines)</strong></summary>
            <div>
                <ul><li>- EIMs are grouped into 4 categories:</li></ul>
                
        <details>
            <summary><strong>Classical (Reactive)</strong></summary>
            <div>
                <ul><li>- Inflammatory process at distant sites with shared pathophysiology but different histology.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Associations</strong></summary>
            <div>
                <ul><li>- Coexistence with other immune-mediated disorders.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Complications</strong></summary>
            <div>
                <ul><li>- Includes treatment-induced manifestations.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Wider Associations</strong></summary>
            <div>
                <ul><li>- Other related conditions.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Cutaneous Manifestations of IBD</strong></summary>
            <div>
                <ul><li>- Prevalence ranges from <q><b>10% to 30%</b></q> in IBD patients.</li><li>- Onset often coincides with disease flares but not always.</li><li>- Prognosis does not always correlate with IBD clinical course.</li></ul>
                
        <details>
            <summary><strong>1. Reactive (Classical) Manifestations</strong></summary>
            <div>
                <ul><li>- Same pathophysiologic mechanisms as IBD but different histopathology.</li></ul>
                
        <details>
            <summary><strong>Erythema Nodosum (EN)</strong></summary>
            <div>
                <ul><li>- <u>The most common</u> cutaneous EIM of IBD.</li></ul>
                
        <details>
            <summary><strong>Epidemiology</strong></summary>
            <div>
                <ul><li>- Overall prevalence: <q>1% to 15%</q> in IBD patients.</li><li>- Recent meta-analysis: <q><b>3% in CD</b></q> and <q><b>1% in UC</b></q>.</li><li>- More common in <b>women</b> and linked to <b>colonic illness</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pathophysiology</strong></summary>
            <div>
                <ul><li>- A type IV (delayed) hypersensitivity reaction to various antigens.</li><li>- Histopathology: Septal inflammation with neutrophils (early) and lymphocytes/giant cells (late).</li><li>- Polarized <b>Th1 response</b> with overexpression of IL-2 and IFN-γ.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Presentation</strong></summary>
            <div>
                <ul><li>- Symmetric, tender, erythematous, warm nodules and raised plaques (<q>1-5 cm</q>).</li><li>- Lesions <u>never ulcerate</u> and heal without atrophy or scarring.</li><li>- Typically located on shins, knees, and ankles.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis & Treatment</strong></summary>
            <div>
                <ul><li>- <b>Diagnosis</b> is clinical. Biopsy only for persistent (>8 weeks) or atypical cases.</li><li>- <b>Treatment</b> focuses on controlling underlying IBD.</li><li>- Lesions self-resolve in <q>3 to 6 weeks</q>.</li><li>- Symptomatic relief: bed rest, compression, analgesics, potassium iodide.</li><li>- Painful lesions: short courses of oral corticosteroids, hydroxychloroquine, anti-TNF agents.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Relevance to IBD</strong></summary>
            <div>
                <ul><li>- Typically follows the clinical course of IBD.</li><li>- CD may raise the risk of EN (unidirectional causality).</li><li>- Associated IBD susceptibility loci: <u>PTGER4, ITGAL, IKZF1, SOCS5</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pyoderma Gangrenosum (PG)</strong></summary>
            <div>
                <ul><li>- The <u>second most common</u> cutaneous EIM.</li></ul>
                
        <details>
            <summary><strong>Epidemiology</strong></summary>
            <div>
                <ul><li>- Prevalence: <q><b>0.6% to 2.6%</b></q> among IBD patients.</li><li>- Significantly associated with <b>female sex</b>, <b>CD</b>, and other EIMs (ocular, joint).</li><li>- More common in Black Africans and those with a family history of UC.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pathophysiology</strong></summary>
            <div>
                <ul><li>- Involves dysregulated neutrophils and T cells (predominantly <b>Th1</b>).</li><li>- Key cytokines: IL-1α, IL-17, IL-23, IL-6, IL-8.</li><li>- Associated genes: <u>PTPN6, PSTPIP1, IL8RA</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Presentation</strong></summary>
            <div>
                <ul><li>- Starts as a papule or pustule ---> progresses to an ulcer with <b>erythematous to violaceous undermined borders</b> and a purulent base.</li><li>- Predilection for trunk, extensor surfaces, and peristomal areas.</li><li>- Exhibits <b>pathergy</b> (lesion enlargement after minor trauma).</li></ul>
                
        <details>
            <summary><strong>Clinical Variants</strong></summary>
            <div>
                <ul><li>- <b>Ulcerative</b>: Most common.</li><li>- <b>Pustular</b>: Almost exclusively seen in acute IBD exacerbations (usually UC).</li><li>- Other variants: Bullous, vegetative, peristomal, postoperative.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>- A diagnosis of <u>exclusion</u>; no specific lab or clinical findings.</li><li>- <b>Biopsy should be avoided</b> as it may cause lesion enlargement due to pathergy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment (See Figure 2)</strong></summary>
            <div>
                <ul><li>- Requires interdisciplinary care with dermatologists.</li></ul>
                
        <details>
            <summary><strong>Local Care</strong></summary>
            <div>
                <ul><li>- <b>Wound care</b>: Gentle cleansing, sterile dressings. <u>No debridement</u> due to pathergy.</li><li>- <b>Topical</b>: Superpotent corticosteroids, tacrolimus.</li><li>- <b>Intralesional</b>: Corticosteroids, methotrexate, ciclosporin A.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Systemic Therapy</strong></summary>
            <div>
                <ul><li>- <b>First line</b>: <q>Systemic corticosteroids</q> (e.g., oral prednisone <b>0.5-2 mg/kg/day</b>).</li><li>- <b>Biologics</b>: Anti-TNF agents (<b>Infliximab</b> is the first drug with RCT for PG), Ustekinumab, IL-1/IL-23 inhibitors.</li><li>- <b>Small Molecules</b>: JAK inhibitors (e.g., Tofacitinib).</li><li>- <u>Caution</u>: <q>IL-17 inhibitors</q> should not be used in IBD patients due to risk of IBD exacerbation.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Relevance to IBD</strong></summary>
            <div>
                <ul><li>- Clinical course may or may not follow intestinal disease activity.</li><li>- Can precede IBD diagnosis in <q>~15%</q> of patients.</li><li>- Associated with increased risk of pouch failure in UC patients with ileal pouch-anal anastomosis.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Sweet Syndrome (SS)</strong></summary>
            <div>
                <ul><li>- A rare neutrophilic dermatosis in IBD.</li></ul>
                
        <details>
            <summary><strong>Epidemiology</strong></summary>
            <div>
                <ul><li>- Prevalence: <q><b><0.3%</b></q> of IBD patients.</li><li>- More frequent with <b>colonic involvement</b>, especially in CD.</li><li>- Can occur before (5.3%), alongside (29.5%), or after (64.2%) IBD diagnosis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pathophysiology</strong></summary>
            <div>
                <ul><li>- Classified as classic (idiopathic), malignancy-associated, or drug-induced.</li><li>- IBD-related SS is the <b>classic type</b>.</li><li>- A drug-induced form can be caused by <q><b>azathioprine (AZA)</b></q>, which is a hypersensitivity reaction independent of thiopurine S-methyltransferase levels.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Presentation</strong></summary>
            <div>
                <ul><li>- Rapid development of tender, erythematous to violaceous papules, plaques, or nodules.</li><li>- Associated with <b>fever</b> and <b>leukocytosis</b>.</li><li>- Lesions typically on upper extremities, face, and neck.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis & Treatment</strong></summary>
            <div>
                <ul><li>- <b>Diagnosis</b> of exclusion; biopsy recommended.</li><li>- Histopathology: Dense diffuse neutrophilic infiltrate in the upper dermis.</li><li>- <b>Treatment</b>: Focus on controlling underlying IBD.</li><li>- <u>First line</u>: <q>Systemic corticosteroids</q> (e.g., prednisone <b>0.5-1 mg/kg/day</b>).</li><li>- <u>Second line</u>: Biologics (infliximab, ustekinumab, vedolizumab).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Relevance to IBD</strong></summary>
            <div>
                <ul><li>- Tends to parallel underlying disease activity.</li><li>- May be a positive prognostic factor for avoiding bowel penetrations or strictures in CD with colonic involvement.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>2. Specific Manifestations</strong></summary>
            <div>
                <ul><li>- Share similar histopathologic features with intestinal disease.</li></ul>
                
        <details>
            <summary><strong>Extraintestinal Crohn's Disease</strong></summary>
            <div>
                <ul><li>- Arises outside the GI tract.</li><li>- Locations: Oral, perianal, or vulvar CD.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>3. Associated Disorders</strong></summary>
            <div>
                <ul><li>- Inflammatory or autoimmune disorders that coexist with IBD and may share risk factors.</li></ul>
                
        <details>
            <summary><strong>Hidradenitis Suppurativa (HS)</strong></summary>
            <div>
                <ul><li>- Chronic, inflammatory, recurrent follicular skin disease.</li></ul>
                
        <details>
            <summary><strong>Epidemiology & Pathophysiology</strong></summary>
            <div>
                <ul><li>- Elevated risk in both CD (OR 2.12) and UC (OR 1.51) patients.</li><li>- <b>Pathophysiology</b>: Follicular hyperkeratosis ---> occlusion ---> rupture and inflammation.</li><li>- Shared factors with IBD: Gut-skin axis, upregulated TNF-α and IL-17.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Presentation & Diagnosis</strong></summary>
            <div>
                <ul><li>- Painful, deep-seated, inflamed lesions in apocrine gland areas (axillary, inguinal, anogenital).</li><li>- Progresses to abscesses, interconnected sinus tracts, and scars.</li><li>- <b>Diagnosis</b> is clinical; no pathognomonic tests.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment & IBD Relevance</strong></summary>
            <div>
                <ul><li>- <b>Treatment</b>: Lifestyle changes (smoking cessation, weight loss), antibiotics, biologics.</li><li>- For HS with IBD: <q><b>Adalimumab</b></q> (first line) and infliximab can manage both conditions.</li><li>- <b>Relevance</b>: IBD is a causal factor for HS (but not vice versa). HS can also be a paradoxical reaction to anti-TNF therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Psoriasis</strong></summary>
            <div>
                <ul><li>- Chronic inflammatory papulosquamous disease.</li></ul>
                
        <details>
            <summary><strong>Epidemiology & Pathophysiology</strong></summary>
            <div>
                <ul><li>- Occurs in <q><b>3.6% of CD</b></q> and <q><b>2.8% of UC</b></q> patients.</li><li>- <b>Bidirectional causality</b> with IBD has been demonstrated.</li><li>- Shared pathogenesis: JAK/STAT pathway, macrophages, CD4+ T cells.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment & IBD Relevance</strong></summary>
            <div>
                <ul><li>- <b>Treatment</b>: Anti-TNF agents are recommended for both diseases.</li><li>- <u>Warning</u>: Avoid <q><b>IL-17A inhibitors</b></q> due to possible IBD exacerbations.</li><li>- <b>Relevance</b>: IBD may causally increase the risk of psoriasis. Psoriasiform lesions are a common paradoxical effect of anti-TNF therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Associated Disorders</strong></summary>
            <div>
                <ul><li>- A summary of other less common associated conditions.</li></ul>
                
        <details>
            <summary><strong>Rosacea</strong></summary>
            <div>
                <ul><li>- IBD patients are <q>86%</q> more likely to develop rosacea (especially UC).</li><li>- IBD is considered the causal factor, not the reverse.</li><li>- Can also be an adverse event of anti-TNF treatment.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Atopic Dermatitis (AD)</strong></summary>
            <div>
                <ul><li>- Bidirectional relationship suggested, but studies are contradictory.</li><li>- Children with AD may have an increased risk of developing IBD later in life.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Acne Conglobata (AC)</strong></summary>
            <div>
                <ul><li>- Severe inflammatory acne; increased risk in IBD patients.</li><li>- First-line treatment is oral <q><b>isotretinoin (0.5-1.0 mg/kg/day)</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Systemic Lupus Erythematosus (SLE)</strong></summary>
            <div>
                <ul><li>- Higher prevalence of CD reported in SLE patients.</li><li>- However, one study suggests SLE is associated with a <u>lower</u> IBD risk in European populations.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Vitiligo</strong></summary>
            <div>
                <ul><li>- Affects <q>~0.3%</q> of IBD patients (UC=CD).</li><li>- No direct causal relationship demonstrated.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Chronic Urticaria (CU)</strong></summary>
            <div>
                <ul><li>- Significant association found, but no genetic causal relationship demonstrated.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Leukocytoclastic Vasculitis (LCV)</strong></summary>
            <div>
                <ul><li>- In <b>UC</b>, it is a true association, often occurring during a flare.</li><li>- In <b>CD</b>, it is mostly secondary to biologic therapy (infliximab, adalimumab).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Alopecia Areata (AA)</strong></summary>
            <div>
                <ul><li>- Affects <q>6 in 1000</q> IBD patients.</li><li>- No causative relationship has been demonstrated.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>4. Complications: Side Effects of IBD Therapies</strong></summary>
            <div>
                <ul><li>- Biologics can cause "paradoxical" adverse events, resembling conditions they normally treat.</li></ul>
                
        <details>
            <summary><strong>Paradoxical Cutaneous Reactions</strong></summary>
            <div>
                <ul><li>- Occur in <q><b>25.9%</b></q> of patients on anti-TNF in prospective studies.</li><li>- Pediatric patients seem more affected.</li></ul>
                
        <details>
            <summary><strong>Implicated Drugs</strong></summary>
            <div>
                <ul><li>- <b>Anti-TNF</b>: <q><b>Infliximab (67.5%)</b></q> and <q><b>adalimumab (30.5%)</b></q> are most common.</li><li>- <b>Vedolizumab</b>: Reports of induced PG, SS, and psoriasiform dermatitis.</li><li>- <b>Ustekinumab/Risankizumab</b>: Rare reports of paradoxical psoriasis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Common Manifestations</strong></summary>
            <div>
                <ul><li>- <b>Most reported</b>: <q>Psoriasis/psoriasiform rash</q>.</li><li>- Others: HS, PG, EN, vasculitis, and SLE/lupus-like lesions.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pathophysiology & Risk Factors</strong></summary>
            <div>
                <ul><li>- Mechanism: Cytokine imbalance (increased IFN-α) ---> Th17-induced inflammation.</li><li>- <b>Risk Factors</b> for psoriasiform lesions: <q>female sex, younger age, smoking, and ileocolonic CD</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>- <u>Avoid discontinuation</u> of anti-TNF if possible.</li><li>- Most cases respond well to topical dermatological treatments.</li><li>- Severe cases: Switch to another biologic (e.g., ustekinumab, vedolizumab).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>JAK Inhibitor-Associated Reactions</strong></summary>
            <div>
                <ul><li>- Associated with increased risk for <b>Herpes Zoster (HZ)</b>.</li><li>- Also associated with acneiform reactions (<q>9.7%</q> of patients on upadacitinib).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Herpes Zoster (HZ) in IBD</strong></summary>
            <div>
                <ul><li>- Infectious vesiculopapular skin disease from reactivation of Varicella Zoster Virus (VZV).</li></ul>
                
        <details>
            <summary><strong>Risk in IBD Patients</strong></summary>
            <div>
                <ul><li>- IBD patients have a <q><b>1.68-fold higher risk</b></q> for HZ compared to the general population.</li><li>- <b>Risk Factors</b>: Age >50, immunosuppression, active IBD, Asian race.</li></ul>
                
        <details>
            <summary><strong>Drug-Specific Risks</strong></summary>
            <div>
                <ul><li>- Increased risk linked to: <q>corticosteroids, thiopurines, and combination therapies</q>.</li><li>- <b>JAK Inhibitors</b>: A meta-analysis identified a significant association of HZ with <q><b>tofacitinib (10mg twice a day)</b></q> and <q><b>upadacitinib (45mg every day)</b></q>.</li><li>- <b>Safest option</b>: Anti-IL-23 agents showed no significant rise in HZ risk.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Presentation & Complications</strong></summary>
            <div>
                <ul><li>- Unilateral, dermatomal vesiculopapular rash, preceded by neuropathic symptoms.</li><li>- <b>Complications</b>: Postherpetic neuralgia is the most frequent. IBD patients have increased risk for all HZ complications except ophthalmic ones.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis & Treatment</strong></summary>
            <div>
                <ul><li>- <b>Diagnosis</b>: Mostly clinical. <q>PCR for VZV DNA</q> from active lesions is the gold standard.</li><li>- <b>Treatment</b>: Initiate systemic antivirals <q><u><72 hours</u></q> after rash onset.</li></ul>
                
        <details>
            <summary><strong>Antiviral Regimens</strong></summary>
            <div>
                <ul><li>- <u>Immunocompetent</u>: Oral <q><b>valaciclovir 1000mg 3 times a day for 7-10 days</b></q>.</li><li>- <u>Immunosuppressed</u>: Intravenous <q><b>aciclovir (8-12mg/kg 3 times a day for 7 days)</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Prevention</strong></summary>
            <div>
                <ul><li>- <b>Vaccination</b> can greatly reduce risk.</li><li>- The recombinant zoster vaccine (<b>Shingrix</b>) is preferred over live attenuated vaccines, which are contraindicated in immunocompromised individuals.</li><li>- Recommend vaccination for all IBD patients <q><b>>50 years</b></q> and high-risk patients regardless of age.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Special Considerations: Pregnancy</strong></summary>
            <div>
                <ul><li>- Pregnancy can affect IBD course via hormonal alterations and may increase EIM risk.</li></ul>
                
        <details>
            <summary><strong>Common Dermatoses</strong></summary>
            <div>
                <ul><li>- <b>Erythema Nodosum (EN)</b> is the most common shared dermatosis between IBD and pregnancy.</li><li>- <b>Pyoderma Gangrenosum (PG)</b> is much rarer.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment Safety in Pregnancy</strong></summary>
            <div>
                <ul><li>- <b>Considered Safe</b>: <q>Anti-TNF agents</q> (though may increase risk of abortion/preterm birth), 5-ASA, sulfasalazine, thiopurines.</li><li>- <u>Note</u>: <q>Certolizumab</q> does not cross the placenta.</li><li>- <b>Use with Caution</b>: Corticosteroids (short courses for flares).</li><li>- <b><u>ABSOLUTELY CONTRAINDICATED</u></b>: <q><b>Methotrexate (MTX)</b></q> and <q><b>thalidomide</b></q> due to teratogenic effects.</li><li>- <b>Not Recommended</b>: JAK inhibitors and ozanimod due to limited data.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Interdisciplinary Care: Role of Dermatologists</strong></summary>
            <div>
                <ul><li>- Essential for diagnosing and managing IBD-associated skin disorders.</li><li>- Expertise allows for accurate diagnosis, avoiding unnecessary IBD treatment modifications.</li><li>- Helps manage paradoxical reactions, often allowing continuation of systemic IBD therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
